Navigation Links
Bernstein Liebhard LLP Launches Pradaxa Lawsuit Website Providing Information on Mounting Pradaxa Litigation, Side Effects
Date:1/20/2013

New York, NY (PRWEB) January 20, 2013

Bernstein Liebhard LLP has launched a new Pradaxa lawsuit website dedicated to informing the public about the harmful side effects that may stem from the blood thinner manufactured by Boehringer-Ingelheim Pharmaceuticals Inc. The information provided by the firm’s new Pradaxa website is vital to anyone seeking to file a Pradaxa lawsuit.

Bernstein Liebhard LLP is currently offering free and confidential Pradaxa lawsuit evaluations to patients who have sustained the following injuries:

  •     Gastrointestinal (stomach) bleeding;
  •     Cerebral hemorrhaging (bleeding in the brain);
  •     Severe internal bleeding following a minor trauma, such as a fall; or
  •     Death from serious internal bleeding.

“We are receiving more and more inquiries from people who claim to have suffered life-threatening Pradaxa bleeding side effects. Our new website will help provide information about potential Pradaxa side effects, as well as updates on the mounting number of Pradaxa lawsuits being filed by people around the U.S.," says Bernstein Liebhard LLP, a nationwide law firm representing the victims of drugs and medical devices.

Pradaxa, a blood thinner prescribed to reduce the risk of stroke and embolism in patients with non-valvular atrial fibrillation, was approved by the U.S. Food and Drug Administration (FDA) in 2010. In 2011, the FDA received reports of 3,781 side effects and 542 deaths tied to the blood thinner, according to a recent article from Bloomberg.com.*

Patients with artificial heart valves were recently found to be at a heightened risk for suffering Pradaxa side effects. Following this revelation, the FDA issued a public health communication on December 19, 2012 informing health care providers and the public that Pradaxa should not be used to prevent stroke or blood clots in patients with mechanical heart valves. The agency also announced that all health care providers would be receiving “Dear Doctor Letters” from the company alerting them of this change.**

Pradaxa Lawsuits
A number of Pradaxa lawsuits have already been filed on behalf of patients who experienced side effects associated with the drug. These Pradaxa lawsuits have since been consolidated into the multidistrict litigation, In re: Pradaxa Product Liability Litigation (“MDL No. 2385”) underway in the U.S. District Court for the Southern District of Illinois and are pending before Judge David R. Herndon. According to a report in the Madison Record, 176 Pradaxa lawsuits were pending in this MDL as of Jan. 10, 2013.***

Patients who took Pradaxa and suffered excessive bleeding side effects may be entitled to file a Pradaxa lawsuit to receive compensation for lost wages, medical expenses, as well as any pain and suffering they may have been caused as a result of their injury. Learn more about Pradaxa side effects by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/ or by contacting a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.

*bloomberg.com/news/2012-12-11/boehringer-sued-by-hundreds-over-bleeding-tied-to-pradaxa.html
**fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm333209.htm
***madisonrecord.com/issues/895-product-liability/251351-herndon-reports-steady-progress-in-yaz-pradaxa-litigation

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/pradaxa-lawsuit/pradaxa-bleeding/prweb10340318.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Actos Bladder Cancer Lawsuits: Next Status Conference in Federal Actos Litigation Scheduled for January 24, 2013, Bernstein Liebhard LLP Reports
2. Pradaxa Side Effect Problems Continue, as New Report Finds Pradaxa Bleeding More Likely to Result in Death, Bernstein Liebhard LLP Reports
3. Bernstein Liebhard LLP Launches Mirena IUD Lawsuit Website Providing Information on Side Effects, Growing Litigation
4. Da Vinci Surgery Robot Lawsuit Website Launched by Bernstein Leibhard LLP to Inform Public about Potential Da Vinci Surgery Complications
5. 176 Pradaxa Lawsuits Now Pending in Federal Litigation, Discovery Well Underway, Bernstein Liebhard LLP Reports
6. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
7. Stryker Hip Recall Lawsuits Being Evaluated by Bernstein Liebhard LLP, Following Recall of Stryker Rejuvenate and ABG II Modular Neck Stems
8. DePuy ASR Hip Recall, Transvaginal Mesh Lawsuit Updates: Bernstein Liebhard LLP Looks Forward to Start of First Bellwether Trials in New Year
9. Propecia Lawsuits Being Investigated by Bernstein Liebhard LLP, as Propecia Litigation Pending in New Jersey Superior Court Continues to Move Forward
10. Pradaxa Lawsuits Being Investigated by Bernstein Liebhard LLP, as Next Conference in Federal Pradaxa Litigation Set for January 10th
11. New Metal-on-Metal Hip Implant Study Emphasizes Importance of Patients’ Symptoms in Evaluating the Need for Hip Replacement Revisions, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: